Company news
Arovella Therapeutics Limited news in 2019
Arovella Therapeutics Limited's news releases, calls and decks from 2019, newest first.
SANOFI and SUDA Entered Into A Feasibility Agreement
December 8, 2019
SUDA Signs Co-Development Deal With Ordesa
December 4, 2019
SUDA Appoints Dr Michael Baker CEO
November 26, 2019
Case For Share Consolidation and Appendix 3A.3
November 3, 2019
SUDA Finalises Agreement With Cann Pharmaceutical
October 29, 2019
Response to ASX Query regarding Accounts
October 2, 2019
Manaing Director and CEO Resignation
September 23, 2019
ArTiMist Appeal Lodged With TGA
August 8, 2019
ZolpiMist Clinical Results Published
August 6, 2019
European Anagrelide Cancer Patent
July 21, 2019
Supplementary Prospectus
June 27, 2019
Rights Issue Closes Significantly Oversubscribed
June 25, 2019
SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
June 4, 2019
Prospectus For Renounceable Pro Rata Offer
June 2, 2019
Rights Issue To Raise Up To $3.44 Million
June 2, 2019
Product Development Market Update
May 12, 2019
ArTiMist Regulatory Update
April 18, 2019
Appendix 4C Amended
February 4, 2019